Hoffman: FTC won't accept pipeline divestitures in certain mergers

Charles McConnell

05 February 2018

Credit: Freedom Film

The acting director of the Federal Trade Commission's bureau of competition has said that the commission will no longer accept the divestiture of pipeline products to remedy anticompetitive mergers in the inhalant and injectable drug industries.

Subscribe to Global Competition Review

Subscribe to unlock unlimited access

Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.

Subscribe now

Already have access? Login below

Charles McConnell

View full biography

Author | Senior correspondent, Global Competition Review

[email protected]

Tipline

Bayewatch: The Tipline for 28 November 2023
NERA Economic Consulting’s Michael Baye has had a busy couple of weeks. Following a jury trial win just before Thanksgiving, which found that egg producers and trade groups conspired to restrict output, the former head of the Federal Trade Commission’s bureau of economics is now arguing for treble damages in that lawsuit. Meanwhile, he also joined a list of ex-enforcers calling on the US agencies to rethink their proposed merger guidelines.
Better together: The Tipline for 27 November 2023
Virtue, Liberty and Independence (and Antitrust): The Tipline for 24 November 2023